Literature DB >> 25708195

CD47 signaling pathways controlling cellular differentiation and responses to stress.

David R Soto-Pantoja1, Sukhbir Kaur, David D Roberts.   

Abstract

CD47 is a widely expressed integral membrane protein that serves as the counter-receptor for the inhibitory phagocyte receptor signal-regulatory protein-α (SIRPα) and as a signaling receptor for the secreted matricellular protein thrombospondin-1. Recent studies employing mice and somatic cells lacking CD47 have revealed important pathophysiological functions of CD47 in cardiovascular homeostasis, immune regulation, resistance of cells and tissues to stress and chronic diseases of aging including cancer. With the emergence of experimental therapeutics targeting CD47, a more thorough understanding of CD47 signal transduction is essential. CD47 lacks a substantial cytoplasmic signaling domain, but several cytoplasmic binding partners have been identified, and lateral interactions of CD47 with other membrane receptors play important roles in mediating signaling resulting from the binding of thrombospondin-1. This review addresses recent advances in identifying the lateral binding partners, signal transduction pathways and downstream transcription networks regulated through CD47 in specific cell lineages. Major pathways regulated by CD47 signaling include calcium homeostasis, cyclic nucleotide signaling, nitric oxide and hydrogen sulfide biosynthesis and signaling and stem cell transcription factors. These pathways and other undefined proximal mediators of CD47 signaling regulate cell death and protective autophagy responses, mitochondrial biogenesis, cell adhesion and motility and stem cell self-renewal. Although thrombospondin-1 is the best characterized agonist of CD47, the potential roles of other members of the thrombospondin family, SIRPα and SIRPγ binding and homotypic CD47 interactions as agonists or antagonists of signaling through CD47 should also be considered.

Entities:  

Keywords:  Autophagy; Myc; hydrogen sulfide; immune regulation; integrin signaling; nitric oxide; radioresistance; stem cells

Mesh:

Substances:

Year:  2015        PMID: 25708195      PMCID: PMC4822708          DOI: 10.3109/10409238.2015.1014024

Source DB:  PubMed          Journal:  Crit Rev Biochem Mol Biol        ISSN: 1040-9238            Impact factor:   8.250


  162 in total

1.  Thrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47.

Authors:  Sukhbir Kaur; Gema Martin-Manso; Michael L Pendrak; Susan H Garfield; Jeff S Isenberg; David D Roberts
Journal:  J Biol Chem       Date:  2010-10-05       Impact factor: 5.157

2.  Interactions between CD47 and thrombospondin reduce inflammation.

Authors:  Laurence Lamy; Arnaud Foussat; Eric J Brown; Paul Bornstein; Michel Ticchioni; Alain Bernard
Journal:  J Immunol       Date:  2007-05-01       Impact factor: 5.422

3.  CD47 deficiency confers cell and tissue radioprotection by activation of autophagy.

Authors:  David R Soto-Pantoja; Thomas W Miller; Michael L Pendrak; William G DeGraff; Camille Sullivan; Lisa A Ridnour; Mones Abu-Asab; David A Wink; Maria Tsokos; David D Roberts
Journal:  Autophagy       Date:  2012-08-09       Impact factor: 16.016

4.  Normal ligand binding and signaling by CD47 (integrin-associated protein) requires a long range disulfide bond between the extracellular and membrane-spanning domains.

Authors:  R A Rebres; L E Vaz; J M Green; E J Brown
Journal:  J Biol Chem       Date:  2001-07-13       Impact factor: 5.157

5.  CD47 in the tumor microenvironment limits cooperation between antitumor T-cell immunity and radiotherapy.

Authors:  David R Soto-Pantoja; Masaki Terabe; Arunima Ghosh; Lisa A Ridnour; William G DeGraff; David A Wink; Jay A Berzofsky; David D Roberts
Journal:  Cancer Res       Date:  2014-10-08       Impact factor: 12.701

6.  Membrane raft association of CD47 is necessary for actin polymerization and protein kinase C theta translocation in its synergistic activation of T cells.

Authors:  R A Rebres; J M Green; M I Reinhold; M Ticchioni; E J Brown
Journal:  J Biol Chem       Date:  2000-12-12       Impact factor: 5.157

7.  CD47 augments Fas/CD95-mediated apoptosis.

Authors:  Partha P Manna; Julie Dimitry; Per-Arne Oldenborg; William A Frazier
Journal:  J Biol Chem       Date:  2005-05-24       Impact factor: 5.157

8.  Radioprotection in normal tissue and delayed tumor growth by blockade of CD47 signaling.

Authors:  Justin B Maxhimer; David R Soto-Pantoja; Lisa A Ridnour; Hubert B Shih; William G Degraff; Maria Tsokos; David A Wink; Jeff S Isenberg; David D Roberts
Journal:  Sci Transl Med       Date:  2009-10-21       Impact factor: 17.956

9.  Ubiquilin-1 protects cells from oxidative stress and ischemic stroke caused tissue injury in mice.

Authors:  Yanying Liu; Lanhai Lü; Casey L Hettinger; Gaofeng Dong; Dong Zhang; Khosrow Rezvani; Xuejun Wang; Hongmin Wang
Journal:  J Neurosci       Date:  2014-02-19       Impact factor: 6.167

10.  Ubiquilin4 is an adaptor protein that recruits Ubiquilin1 to the autophagy machinery.

Authors:  Dong Yun Lee; David Arnott; Eric J Brown
Journal:  EMBO Rep       Date:  2013-03-05       Impact factor: 8.807

View more
  72 in total

1.  CD47 Receptor Globally Regulates Metabolic Pathways That Control Resistance to Ionizing Radiation.

Authors:  Thomas W Miller; David R Soto-Pantoja; Anthony L Schwartz; John M Sipes; William G DeGraff; Lisa A Ridnour; David A Wink; David D Roberts
Journal:  J Biol Chem       Date:  2015-08-26       Impact factor: 5.157

Review 2.  The role of CD47 in pathogenesis and treatment of renal ischemia reperfusion injury.

Authors:  Jeffrey S Isenberg; David D Roberts
Journal:  Pediatr Nephrol       Date:  2018-11-03       Impact factor: 3.714

3.  Regulation of Cellular Redox Signaling by Matricellular Proteins in Vascular Biology, Immunology, and Cancer.

Authors:  David D Roberts; Sukhbir Kaur; Jeffrey S Isenberg
Journal:  Antioxid Redox Signal       Date:  2017-09-08       Impact factor: 8.401

4.  Natural Killer Cell Recruitment and Activation Are Regulated by CD47 Expression in the Tumor Microenvironment.

Authors:  Pulak Ranjan Nath; Dipasmita Pal-Nath; Ajeet Mandal; Margaret C Cam; Anthony L Schwartz; David D Roberts
Journal:  Cancer Immunol Res       Date:  2019-07-30       Impact factor: 11.151

Review 5.  From leukocyte recruitment to resolution of inflammation: the cardinal role of integrins.

Authors:  Ioannis Kourtzelis; Ioannis Mitroulis; Janusz von Renesse; George Hajishengallis; Triantafyllos Chavakis
Journal:  J Leukoc Biol       Date:  2017-03-14       Impact factor: 4.962

6.  MicroRNA-133a suppresses the proliferation, migration, and invasion of laryngeal carcinoma cells by targeting CD47.

Authors:  Hui Li; Yan Wang; Yan-Zhong Li
Journal:  Tumour Biol       Date:  2016-10-11

Review 7.  Divergent modulation of normal and neoplastic stem cells by thrombospondin-1 and CD47 signaling.

Authors:  Sukhbir Kaur; David D Roberts
Journal:  Int J Biochem Cell Biol       Date:  2016-05-06       Impact factor: 5.085

8.  Role of Thrombospondin-1 in Mechanotransduction and Development of Thoracic Aortic Aneurysm in Mouse and Humans.

Authors:  Yoshito Yamashiro; Bui Quoc Thang; Seung Jae Shin; Caroline Antunes Lino; Tomoyuki Nakamura; Jungsil Kim; Kaori Sugiyama; Chiho Tokunaga; Hiroaki Sakamoto; Motoo Osaka; Elaine C Davis; Jessica E Wagenseil; Yuji Hiramatsu; Hiromi Yanagisawa
Journal:  Circ Res       Date:  2018-08-31       Impact factor: 17.367

Review 9.  Thrombospondin-1 interactions regulate eicosanoid metabolism and signaling in cancer-related inflammation.

Authors:  Manuel U Ramirez; Elizabeth R Stirling; Nancy J Emenaker; David D Roberts; David R Soto-Pantoja
Journal:  Cancer Metastasis Rev       Date:  2018-09       Impact factor: 9.264

10.  Bone marrow mesenchymal stromal cells with CD47 high expression via the signal transducer and activators of transcription signaling pathway preventing myocardial fibrosis.

Authors:  Wei Deng; Qing-Wei Chen; Xing-Sheng Li; Zhong-Ming Yuan; Gui-Qiong Li; Da-Zhi Ke; Li Wang; Zhi-Qing Wu; Shi-Lan Luo
Journal:  Int J Clin Exp Pathol       Date:  2015-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.